| __timestamp | Amphastar Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 72471000 |
| Thursday, January 1, 2015 | 46974000 | 89204000 |
| Friday, January 1, 2016 | 47298000 | 106010000 |
| Sunday, January 1, 2017 | 50918000 | 137905000 |
| Monday, January 1, 2018 | 58044000 | 159888000 |
| Tuesday, January 1, 2019 | 63109000 | 158425000 |
| Wednesday, January 1, 2020 | 65157000 | 200677000 |
| Friday, January 1, 2021 | 68920000 | 304759000 |
| Saturday, January 1, 2022 | 66592000 | 377221000 |
| Sunday, January 1, 2023 | 80393000 | 336361000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, understanding financial trends is crucial. Over the past decade, Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Supernus Pharmaceuticals saw a staggering 364% increase in SG&A expenses, peaking in 2022. This growth reflects their aggressive expansion and investment in marketing and administration. In contrast, Amphastar Pharmaceuticals experienced a more modest 99% rise, indicating a more conservative approach. Notably, 2023 marked a significant year for Amphastar, with a 21% jump in expenses, possibly signaling a strategic shift. These trends highlight the differing strategies of these companies in navigating the pharmaceutical market. Investors and analysts should consider these financial insights when evaluating the future potential and strategic direction of these firms.
Novartis AG vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? GSK plc or Supernus Pharmaceuticals, Inc.
GSK plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs Supernus Pharmaceuticals, Inc. Trends and Insights
Grifols, S.A. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Verona Pharma plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Amphastar Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Amphastar Pharmaceuticals, Inc. vs MannKind Corporation Trends and Insights